Enhancing Medication Risk Communication in Developing Countries: A Mixed Method Survey Among Doctors and Pharmacists in Malaysia

Rema Panickar
University of Malaya

Zoriah Aziz (✉️ zoriah@um.edu.my)
University of Malaya

Adeeba Kamarulzaman
University of Malaya

Research Article

Keywords: safety information, alerts, predictors, survey, healthcare professionals, pharmacovigilance, risk minimization

Posted Date: February 11th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1287503/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Medication risk communication is essential to ensure the safe use of medicines. However, very few nations worldwide have established effective risk communication systems. To date, the effectiveness of risk communication among healthcare professionals in Malaysia has never been evaluated. Our study aimed to (i) evaluate doctors’ and pharmacists’ awareness of risk communication methods; (ii) identify factors predicting the usefulness of these methods; and (iii) compare respondents’ preferences for risk communication to outline suggestions for enhancement.

Methods: We conducted a nationwide cross-sectional survey covering four commonly used risk communications, namely a national drug bulletin, safety alerts, Direct Healthcare Professional Communication letters (DHPCs), and educational materials. Multiple logistic regression analysis was used to determine the association between independent variables and the usefulness of risk communication. We performed qualitative analysis to gain insights on respondents’ perspectives on risk communication.

Results: Of the 1146 responses received, 650 were from pharmacists (56.7%). Among the four methods surveyed, 71.5% of respondents were aware of educational materials, while awareness of the other three methods ranged from 20.7% to 53.9%. Pharmacists had higher awareness of all four methods compared to doctors. Private sector respondents were more aware of DHPCs compared to those from the public sector. The strongest predictors for finding risk communication useful were being a pharmacist [odds ratio (OR) = 18.2; 95% CI (10.98-30.07); \( p < 0.001 \)], having \( \geq 30 \) years’ work experience [OR = 4.9; 95% CI 1.98-12.08; \( p < 0.001 \)], and working in the pharmaceutical industry [OR = 4.6; 95% CI (1.08-19.72); \( p = 0.039 \)]. Both doctors and pharmacists preferred risk communication in the English-language and electronic format. However, other preferences differed between the professions and sectors. Analysis of free-text comments revealed five core themes to guide risk communication enhancement strategies.

Conclusions: Risk communication awareness differed between public and private sector doctors and pharmacists depending on communication source. Integrating our findings with the theory of effective communication, we provide suggestions for developing strategic plans on enhancing risk communication. Public-private sector collaboration is key in ensuring risk communication effectiveness.

Background

The COVID-19 pandemic has highlighted the importance of effective risk communication in tackling issues such as vaccine-hesitancy and new treatment choices.[1, 2] While medication use is essential, it comes with its own risks and may cause serious harm because of improper use, medication errors, or adverse drug reactions (ADRs).[3] Accurate, timely, and evidence-based communication to all stakeholders is vital to reduce the risk of ADRs, fear, confusion, and inappropriate medication use.[4] Medication risk communication involves a trillion-dollar industry[5] and a vast amount of time as well as
resources. However, achievable and sustainable steps to implement effective medication risk communication worldwide remain elusive.[6]

Risk communication occurs at every stage of the pharmacovigilance risk management process, [7] encompassing the exchange of information and advice on medication safety between experts or regulatory officials and medicinal product users. The ultimate aim is to allow informed therapeutic decisions to be made by healthcare professionals and the public.[8, 9] While communication is a fundamental process of life, communicating the risks of medicinal products is often complicated.[10] Currently, very few countries have proven effective communication strategies in place.[6] The World Health Organization's (WHO) decade-long efforts to enhance risk communication[11] continue with the latest guidelines on managing an infodemic.[1] WHO emphasizes the need to understand the knowledge, perceptions, beliefs, and practices of all stakeholders[9, 11] while tailoring guidance to encompass the latest advances in communication methods.[1]

In Malaysia, medication risk communication is coordinated by the Pharmacovigilance Section of the National Pharmaceutical Regulatory Agency (NPRA). NPRA is the national regulatory authority tasked with ensuring the quality, efficacy and safety of pharmaceutical products in Malaysia. Risk communication is carried out at various levels, for example between regulators and healthcare professionals, industry and the public, or between healthcare professionals and their patients. Currently, most NPRA risk communication targets doctors and pharmacists, who comprise the main handlers of medication.[12] Various risk communication methods have been used in Malaysia over the past 30 years, including press releases, a national bulletin, safety alerts via email or social media, product package inserts, Direct Healthcare Professional Communication (DHPC) letters, and educational materials. However, our previous study[13] revealed that the risk communication methods, specifically related to allopurinol, did not have a significant impact on ADR reporting and prescribing practice.

A recent article[14] highlighted the importance of conducting studies specifically to evaluate the preferences of the target audience in terms of content, form and delivery of risk communications. While medication risk communication has been carried out in Malaysia for decades, to the best of our knowledge, the effectiveness of this fundamental activity in influencing the knowledge and practice of healthcare professionals has never been established. Factors associated with the usefulness of medication risk communication have also never been identified and analysed.

This study aimed to (i) evaluate the awareness of doctors and pharmacists on four available risk communication methods, (ii) identify factors that predict the usefulness of these methods, and (iii) compare the preferences of respondents on risk communication. We included qualitative analysis to gain insights on respondents’ perspectives on risk communication and offer suggestions for developing a strategic plan for risk communication enhancement. These findings are important to outline specific suggestions for improving risk communication, which could be implemented in all nations with developing risk communication systems.
Methods

Study design

We conducted a cross-sectional, multicentre, self-administered web-based survey involving doctors and pharmacists across Malaysia from March to June 2021.

Study population

The Malaysian healthcare system is divided into the government-funded public sector and the pay-for-service private sector.[15, 16] The public healthcare sector, estimated to serve approximately 65% of the population, comprises hospitals and health clinics where services are heavily subsidised. Meanwhile, the private sector consists of a network of hospitals, specialist or general practitioner clinics, and retail pharmacies. The types and brands of medicines used in these 2 sectors usually vary because of differences in funding.[15]

The study population comprises all registered doctors and pharmacists in the Malaysian public and private healthcare sectors. As of June 2020, there were 71,041 doctors (51,912 serving with the Ministry of Health - MOH) and 19,341 pharmacists (11,616 serving with the MOH) registered in Malaysia.[17]

Inclusion and exclusion criteria

All fully registered doctors and pharmacists who gave their consent to participate in the online survey were included. Doctors and pharmacists undergoing pre-registration training (house officers and provisionally registered pharmacists) and those not currently practising in Malaysia were excluded.

Sample size

Based on previous surveys involving doctors and pharmacists in Malaysia, the calculated minimum sample size required would be 383, with a 5% margin of error and confidence interval of 95%. [18, 19] However, based on the documented response rate of about 35% for similar studies, the calculated sample size needed for this study was 1100.

Questionnaire

We adapted the English-language survey questions from the Strengthening Collaboration for Operating Pharmacovigilance in Europe (SCOPE) Joint Action Work Package 6: Healthcare Professional Survey,[20] with some modifications based on the literature review. The adapted questionnaire contained six domains with 33 items related to medication risk communication.

Our questionnaire covered four risk communication methods used in Malaysia, namely a national drug bulletin called the Malaysian Adverse Drug Reactions Advisory Committee (MADRAC) bulletin, NPRA safety alerts, DHPCs, and educational materials. Table 1[21, 22] shows a comparison of these four methods. For each method, respondents were asked to respond on (a) their awareness of the method[a],
(b) how useful they find the method, and (c) how likely they would take the action recommended in the communication.

We assessed the preferences of respondents regarding risk communication and perceptions on the factors that may affect their response to the risk communication through eight questions. The questionnaire included five optional free-text boxes allowing respondents to leave comments on each of the four methods and suggestions for improving risk communication.

For assessment of face and content validity of the questionnaire, we distributed the adapted questionnaire to a group of six experts in medication risk communication or pharmacovigilance. The experts were asked to rate their judgment on the relevance of each item to the measured domain using a 4-point Likert scale. We calculated the content validity index (CVI) [see Additional file 1] to allow objective assessment of content validity, using a CVI cut-off score of at least 0.83 as evaluation was carried out by six experts.[23–26] A scale-level CVI averaging (S-CVI/Avg) score of 0.97 was obtained, and we modified the questionnaire according to comments from the expert panel.

**Table 1** Characteristics of the four medication risk communication methods included in this study.[21, 22]
| Risk communication method | MADRAC Bulletin | Safety Alert | DHPC | Educational material |
|---------------------------|----------------|-------------|------|---------------------|
| **Author**                | NPRA           | NPRA        | Product registration holder, reviewed by NPRA | Product registration holder, NPRA, MOH |
| **Target audience**       | Healthcare professionals | Healthcare professionals | Healthcare professionals | Healthcare professionals or patients |
| **Dissemination method**  | Email to healthcare professionals in NPRA mailing list, administrative heads of healthcare facilities, professional associations | By product registration holder directly to healthcare professionals who use the product mentioned in DHPC | By product registration holder or MOH directly to healthcare professionals | By healthcare professionals to patients |
| **Content**               | Local ADR case reports, MADRAC activities, Latest pharmacovigilance activities | Latest or emerging safety issues, Summary of DHPCs | Important changes to medicinal product information. | Additional information to minimize risk of using the product, in addition to package insert information. |
| **Frequency of publication** | Every four months | As required, depending on emerging safety issues. | |

ADR: adverse drug reaction; DHPC: Direct Healthcare Professional Communication letter; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; MOH: Ministry of Health; NPRA: National Pharmaceutical Regulatory Agency

We piloted the questionnaire on a group of 30 doctors and pharmacists among the target population and modified based on feedback obtained. Data from the pilot study were excluded from the analysis.

**Questionnaire distribution**

We used convenience sampling as a list of the complete sampling frame with contact details could not be obtained because of data protection issues. Email invitations to participate in this study were sent out via administrative heads of public healthcare facilities for all states in Malaysia, as well as via professional bodies such as the Malaysian Medical Association, Malaysian Pharmacists Society, and Association of Private Hospitals Malaysia. The email explained the purpose of the study and contained a link to the web-based questionnaire, designed using Google Forms.
Informed consent was obtained from respondents on the first page of the questionnaire. The respondents participated voluntarily and were not given any form of remuneration. We disseminated reminder emails at 3 and 8-weeks following the initial questionnaire distribution.

**Data analysis**

**Quantitative analysis**

We analysed the data using IBM SPSS version 26 (SPSS Inc., Chicago, Illinois). Categorical data were presented as absolute numbers or percentages, while means and standard deviations (SD) were determined for the continuous numerical variables. We used the Pearson Chi-squared test of independence or independent t-test to compare the demographic data as well as preferences of doctors and pharmacists on risk communication. Level of significance (α) was set at 0.05.

We performed multiple logistic regression analyses to determine the association of seven independent variables (gender, ethnicity, designation, work setting, work experience, strata, and training experience) with the usefulness of risk communication methods in Malaysia. The dependent variable “Overall, do you think NPRA risk communication is useful?” is a dichotomous measure coded 1= Yes and 0= No. Univariate logistic regression was performed to identify variables to be included in the model, based on a $p < 0.25$ significance level to ensure identification of variables known to be important.[27] The best fit model was selected using the Hosmer-Lemeshow test and classification table.

**Qualitative analysis**

We analysed responses obtained from free-text comments using manual thematic analysis, according to the six-phase procedure outlined by Braun and Clarke (2019).[28] Two researchers (RP, ZA) examined the data before independently assigning initial codes. The codes were reviewed and grouped together through consensus among the two members to identify common themes. We then reviewed these themes before generating a thematic map for the entire dataset. Coding and resulting theme generation were verified by the supervisory team.

**Footnote:**

[a] Four answer options were given [1 = Yes, I have seen and read it, 2 = Yes, I have seen but have never read it, 3 = No, I have heard of but never seen it, 4 = No, I have never heard of it].

[b] A 5-point Likert scale was used (1 = not useful at all, 2 = not very useful, 3 = neutral, 4 = useful, 5 = very useful).

[c] A 5-point Likert scale was used (1 = never, 2 = sometimes, 3 = in half of the cases, 4 = often, 5 = always).

**Results**

**Socio-demographic characteristics**
A total of 1146 healthcare professionals completed the survey, comprising 650 pharmacists (56.7%) and 496 doctors (43.3%).[29] Table 2 shows details of the respondents’ characteristics. Most respondents (66%) were female with a mean age of 37.4 ± 8.3 years. Over 80% (n=922) of the respondents were healthcare professionals practicing in the public sector, and the majority (85.5%) were from urban areas. A significantly higher percentage of pharmacists reported having attended training on medication safety or risk communication compared to doctors (72.9% vs. 50.2%; \( p < 0.001 \)).

The preferred methods of keeping medicines’ knowledge up-to-date varied slightly between doctors and pharmacists. Attending training or courses was the top preference for pharmacists (83.5%) while doctors preferred using medicines reference books (61%). Pharmacists expressed a significantly higher preference for the NPRA website or bulletin compared to doctors (57% vs. 16.5%; \( p < 0.001 \)), while more doctors preferred referring to medical journals (50.8% vs. 40.5%; \( p < 0.001 \)).

Table 2 Socio-demographics of respondents (\( N = 1146 \))
| Demographics               | Pharmacists (n=650) | Doctors (n=496) | p value |
|----------------------------|---------------------|-----------------|---------|
|                            | n (%)               | n (%)           |         |
| **Gender**                |                     |                 |         |
| Male                       | 142 (21.8)          | 248 (50.0)      | < 0.001 |
| Female                     | 508 (78.2)          | 248 (50.0)      |         |
| **Age (years)**           |                     |                 |         |
| Mean ± SD                  | 35.6 ± 6.9          | 39.8 ± 9.2      | < 0.001 |
| Range                      | 25 to 69            | 27 to 75        |         |
| **Ethnicity**             |                     |                 |         |
| Malay                      | 268 (41.2)          | 189 (38.1)      | < 0.001 |
| Chinese                    | 304 (46.8)          | 152 (30.6)      | -       |
| Indian                     | 54 (8.3)            | 141 (28.4)      | -       |
| Others                     | 24 (3.7)            | 14 (2.8)        | -       |
| **Main employment setting**|                     |                 |         |
| **Public sector**          |                     |                 | < 0.001 |
| Hospital-based             | 300 (46.2)          | 264 (53.2)      |         |
| Community-based            | 109 (16.8)          | 84 (16.9)       |         |
| Administrative             | 113 (17.4)          | 50 (10.1)       |         |
| Others                     | 4 (0.6)             | 3 (0.6)         |         |
| **Private sector**         |                     |                 | < 0.001 |
| Hospital-based             | 40 (6.2)            | 30 (6.0)        |         |
| Community-based            | 52 (8.0)            | 60 (12.1)       |         |
| Pharmaceutical industry    | 30 (4.6)            | 2 (0.4)         |         |
| Others                     | 2 (0.3)             | 3 (0.6)         |         |
| **Location strata**        |                     |                 |         |
| Urban                      | 541 (83.2)          | 439 (88.5)      | 0.012   |
| Rural | 109 (16.8) | 57 (11.5) |
|-------|------------|------------|
| Work experience (years) | Mean ± SD | 11.1 ± 6.3 | 14.1 ± 8.5 | < 0.001 |
| Attended training on medication safety | Yes | 474 (72.9) | 249 (50.2) | < 0.001 |
| No | 176 (27.1) | 247 (49.8) |
| Preferred methods of keeping medicines knowledge up-to-date | Training or courses | 543 (83.5) | 268 (54.0) | < 0.001 |
| Product package inserts or Consumer medication information leaflets | 471 (72.5) | 223 (45.0) | < 0.001 |
| Medicines reference book | 371 (57.1) | 303 (61.0) | 0.172 |
| NPRA website or bulletin | 371 (57.1) | 82 (16.5) | < 0.001 |
| A mobile phone application | 347 (53.4) | 183 (36.9) | < 0.001 |
| Medical journals | 263 (40.5) | 252 (50.8) | < 0.001 |

Statistically significant $p$-values are shown in bold

NPRA: National Pharmaceutical Regulatory Agency, SD: standard deviation

**Awareness of the four risk communication methods**

**Overall awareness and usefulness**

**Fig. 1** compares respondents’ awareness of the four risk communication methods surveyed, how useful they find each method, and how often they take the recommended risk minimization actions. Overall, 71.5% of respondents had seen and read educational materials,[29] while only 20.7% were aware of DHPCs. **Fig. 1(a)** shows that pharmacists had significantly higher awareness of all four methods compared to doctors. Over 70% of pharmacists had seen and read the MADRAC Bulletin and NPRA Safety Alerts, as opposed to less than 26% of doctors. Over 60% of doctors had never heard of the MADRAC Bulletin and DHPCs.

More than 80% of respondents found each of the four methods useful or very useful, with the highest usefulness reported for educational materials (90.2%), as shown in **Fig. 1(b)**. Respondents received
educational materials most often from pharmaceutical companies (56.1%), compared to from NPRA (28.2%) or other MOH sources (40.8%).

**Fig. 1(c)** shows that DHPCs were the most likely risk communication method to encourage respondents to take the recommended risk minimization actions, with 67.2% “often” or “always” taking the recommended action, followed by NPRA Safety Alerts (61.9%), and the MADRAC Bulletin (47.9%).

**Comparison of awareness between public and private sectors**

*Fig. 2* illustrates that more than 70% of pharmacists practicing in the public healthcare sector were aware of the MADRAC Bulletin, NPRA Safety Alerts and educational materials, while private sector pharmacists were significantly more aware of DHPCs (37.1% vs. 23.6%; \( p = 0.002 \)). Public sector doctors had the lowest awareness of all four communication methods.

**Predictors of risk communication usefulness**

*Table 3* shows the results of univariate logistic regression analysis and multivariate analysis. The univariate analysis revealed that the independent variables, namely respondents’ gender, ethnicity, designation, employment setting, urban or rural strata, length of work experience, and training experience, were significantly associated with the dependent variable “find risk communication useful”. In the multivariate analysis, except for the variable gender, all the variables remained significantly associated with the dependent variable. The model explained between 32.4% (Cox and Snell \( R^2 \)) and 44.3% (Nagelkerke \( R^2 \)) of the variance in the dependent variable, and correctly classified 79.2% of cases.

The strongest predictor of finding risk communication useful was being a pharmacist, compared to being a specialist doctor [odds ratio (OR) = 18.2; 95% CI (10.98-30.07); \( p < 0.001 \)]. Respondents with over 30 years’ work experience were more likely to find NPRA risk communication useful compared to those with less than 5 years’ experience [OR= 4.9; 95% CI 1.98-12.08; \( p < 0.001 \)]. Meanwhile, doctors and pharmacists working in pharmaceutical industry were almost 5 times more likely to find the risk communication methods useful compared to those based in private sector community settings [OR= 4.6; 95% CI (1.08-19.72); \( p = 0.039 \)]. Respondents working in public sector administrative departments were more likely to find NPRA risk communication useful compared to those based in private sector community settings [OR= 3.6; 95% CI (1.66-7.99); \( p = 0.001 \)].

*Table 3* Predictors of risk communication usefulness (N = 1146)
| Variables   | Univariate regression | Multivariate regression |
|-------------|-----------------------|-------------------------|
|             | Odds ratio (95% CI)   | p value                 | Adjusted odds ratio (95% CI) | p value |
| Gender      |                       |                         |                             |         |
| Male        | 1                     | 1                       |                             |         |
| Female      | 2.14 (1.66, 2.75)     | <0.001                  | 1.29 (0.92, 1.78)           | 0.140   |
| Age group   |                       |                         |                             |         |
| <45 years   | 1                     |                         |                             |         |
| 45 years and above | 1.16 (0.82, 1.64) | 0.394                  |                             |         |
| Ethnicity   |                       |                         |                             |         |
| Chinese     | 1                     | <0.001                  | 1                           | 0.013   |
| Malay       | 1.30 (0.98, 1.71)     | 0.065                   | 1.85 (1.28, 2.68)           | 0.001   |
| Indian      | 0.54 (0.38, 0.76)     | <0.001                  | 1.35 (0.87, 2.09)           | 0.184   |
| Other       | 1.42 (0.69, 2.93)     | 0.346                   | 1.44 (0.59, 3.50)           | 0.425   |
| Designation |                       |                         |                             |         |
| Specialist  | 1                     | <0.001                  | 1                           | <0.001  |
| General practitioner | 1.84 (0.96, 3.55) | 0.067                  | 2.69 (1.06, 6.84)           | 0.038   |
| Medical officer | 0.92 (0.59, 1.44) | 0.703                  | 1.07 (0.64, 1.79)           | 0.797   |
| Consultant  | 2.03 (1.10, 3.76)     | 0.023                   | 2.06 (1.07, 3.99)           | 0.032   |
| Pharmacist  | 13.97 (9.21, 21.17)   | <0.001                  | 18.17 (10.98, 30.07)        | <0.001  |
| Employment setting |                 |                         |                             |         |
| Private- community | 1 | <0.001 | 1 | 0.013 | |
| Private- hospital | 1.76 (0.94, 3.30) | 0.077 | 1.96 (0.83, 4.61) | 0.124 | |
| Public- community | 1.30 (0.809, 2.08) | 0.281 | 1.53 (0.73, 3.20) | 0.257 | |
| Public- hospital | 1.14 (0.76, 1.71) | 0.537 | 1.54 (0.80, 2.97) | 0.192 | |
| Public- administrative | 3.18 (1.86, 5.42) | <0.001 | 3.64 (1.66, 7.99) | 0.001 | |
| Pharma industry | 7.80 (2.24, 27.09) | 0.001 | 4.61 (1.08, 19.72) | 0.039 | |
| Others      | 1.61 (0.46, 5.67)     | 0.456                   | 1.93 (0.43, 8.62)           | 0.388   |
| Strata      |                       |                         |                             |         |
| Urban       | 1                     | 1                       |                             |         |
### Preferences on risk communication methods

**Table 4** shows the comparison of public and private sector respondents’ preferences on risk communication. A significantly higher percentage of private sector pharmacists (97% vs. 83%; *p* < 0.001) and doctors (94% vs. 83%; *p* = 0.01) prefer the medication risk communication to be in English rather than the Malaysian national language, Bahasa Melayu. Almost all respondents find it useful if the safety message is repeated (96%). Pharmacists had a significantly higher preference for electronic versions of risk communication compared to doctors (73% vs. 61%; *p* < 0.001). However, some groups specifically mentioned a strong preference for hardcopy communications, for example doctors in rural health clinics.

In terms of frequency, pharmacists generally preferred to receive immediate updates of individual safety issues (55%), while doctors preferred monthly updates of all safety issues (47%).

The preferred sources of risk communication (85-96%) were from NPRA and MOH. Private sector pharmacists had a significantly higher preference for receiving risk communication from professional bodies such as the Malaysian Pharmacists Society (72% vs. 58%; *p* = 0.006) and from the pharmaceutical industry (57% vs. 45%, *p* = 0.02). Similarly, a higher percentage of private sector
compared to public sector doctors preferred to receive risk communication from the pharmaceutical industry (46% vs. 31%, \( p < 0.001 \)).

The preferred channels to receive risk communication were via email (74-86%), national clinical guidelines (42-47%) and website (39-46%). Pharmacists reported a higher preference for risk communication via product package inserts (49% vs. 26%, \( p < 0.001 \)) and consumer medication information leaflets (33% vs. 17%, \( p < 0.001 \)) compared to doctors. In contrast, a significantly higher percentage of doctors preferred to receive risk communication via medical journals (34% vs. 23%; \( p < 0.001 \)). Looking at the different sectors, public sector pharmacists (46% vs. 23%; \( p < 0.001 \)) and doctors (31% vs. 19%; \( p < 0.001 \)) expressed a significantly higher preference for risk communication via social media.

The survey revealed that respondents would only read the safety information if it was relevant to their daily practice (74-76%), they trusted the sender (63-72%), and the document was not too lengthy (59-64%). They would take action in response to the safety information if the ADR was severe or caused irreversible harm (77-78%), and if they received sufficient background information on the basis for the safety message (64-66%). A higher percentage of doctors compared to pharmacists reported that they would take action if the safety information was incorporated in clinical or professional society guidelines (55% vs. 48%; \( p = 0.011 \)).

**Table 4** Preferences of pharmacists and doctors on risk communication (\( N = 1146 \))
| Preferences                      | Pharmacists, n (%) | Doctors, n (%) | χ²   | p value |
|---------------------------------|--------------------|---------------|------|---------|
|                                 | Public sector      | Private sector| Public sector | Private sector |
|                                 | (n=526)            | (n=124)       | (n=401) | (n=95) |
| **Language**                    |                    |               |        |         |
| English                         | 438 (83.3)         | 120 (96.8)    | 334 (83.3) | 89 (93.7) |
| *Bahasa Melayu*                 | 88 (16.7)          | 4 (3.2)       | 67 (16.7) | 6 (6.3) |
| **Repeated message**            |                    |               |        |         |
| Yes                             | 508 (96.6)         | 117 (94.4)    | 388 (96.8) | 92 (96.8) |
| **Format**                      |                    |               |        |         |
| Electronic                      | 383 (72.8)         | 94 (75.8)     | 242 (60.3) | 60 (63.2) |
| Hardcopy                        | 58 (11.0)          | 16 (12.9)     | 98 (24.4) | 15 (15.8) |
| No preference                   | 85 (16.2)          | 14 (11.3)     | 61 (15.2) | 20 (21.1) |
| **Preferred frequency**         |                    |               |        |         |
| Immediate update of individual  | 287 (54.6)         | 69 (55.6)     | 152 (37.9) | 47 (49.5) |
| safety issues                   | *24.2*             |               |          | *< 0.001* |
| Weekly update of all safety     | 91 (17.3)          | 35 (28.2)     | 71 (17.7) | 19 (20.0) |
| issues                          |                    |               |          | *0.28*   | *0.595* |
| Monthly update of all safety    | 250 (47.5)         | 50 (40.3)     | 191 (47.6) | 43 (45.3) |
| issues                          |                    |               |          | *0.12*   | *0.731* |
| Quarterly update of all safety   | 47 (8.9)           | 4 (3.2)       | 75 (18.7) | 15 (15.8) |
| issues                          |                    |               |          | *27.7*   | *< 0.001* |
| **Preferred source**            |                    |               |        |         |
| NPRA, Ministry of Health        | 507 (96.4)         | 115 (92.7)    | 341 (85.0) | 79 (83.2) |
| Malaysia                        | *41.4*             |               |          | *< 0.001* |
| Professional body               | 307 (58.4)         | 89 (71.8)     | 264 (65.8) | 71 (74.7) |
|                                | *5.33*             |               |          | *0.021* |
| International regulatory agency  | 294 (55.9)         | 68 (54.8)     | 197 (49.1) | 45 (47.4) |
|                                | *5.38*             |               |          | *0.020* |
| Pharmaceutical companies        | 236 (44.9)         | 70 (56.5)     | 125 (31.2) | 44 (46.3) |
|                                | *19.6*             |               |          | *< 0.001* |
| Preferences                        | Pharmacists, n (%) | Doctors, n (%) | $\chi^2$ | $p$ value |
|-----------------------------------|--------------------|----------------|----------|-----------|
|                                  | Public sector (n=526) | Public sector (n=401) | Private sector (n=124) | Private sector (n=95) |          |
| E-mail                            | 452 (85.9) | 295 (73.6) | 74 (77.9) | 24.6 | $< 0.001$ |
| National clinical guidelines      | 232 (44.1) | 182 (45.4) | 53 (55.8) | 3.49 | 0.062      |
| Website                           | 229 (43.5) | 156 (38.9) | 39 (41.1) | 4.45 | 0.035      |
| Product package insert            | 268 (51.0) | 101 (25.2) | 29 (30.5) | 62.5 | $< 0.001$ |
| Mobile phone text                 | 182 (34.6) | 151 (37.7) | 41 (43.2) | 2.04 | 0.153      |
| Social media                      | 240 (45.6) | 125 (31.2) | 18 (18.9) | 19.3 | $< 0.001$ |
| Medical journal                   | 126 (24.0) | 130 (32.4) | 39 (41.1) | 15.9 | $< 0.001$ |
| Consumer medication information leaflet | 176 (33.5) | 68 (17.0) | 15 (15.8) | 37.8 | $< 0.001$ |

**Factors which contribute to likelihood of reading safety information**

- Information is relevant for daily practice: 405 (77.0) vs. 86 (69.4), $\chi^2 = 0.46, p = 0.500$
- Trust the sender of the safety information: 374 (71.1) vs. 96 (77.4), $\chi^2 = 11.5, p = 0.001$
- The document is not too lengthy: 346 (65.8) vs. 71 (57.3), $\chi^2 = 3.08, p = 0.079$

**Factors which contribute to likelihood of taking action in response to safety information**

- The adverse drug reaction is severe or causes irreversible harm: 410 (77.9) vs. 93 (75.0), $\chi^2 = 0.01, p = 0.924$
- Receive sufficient background information: 352 (66.9) vs. 78 (62.9), $\chi^2 = 0.87, p = 0.352$
- Recommendations are clear: 344 (65.4) vs. 65 (52.4), $\chi^2 = 0.40, p = 0.526$
| Preferences | Pharmacists, n (%) | Doctors, n (%) | $\chi^2$ | $p$ value |
|-------------|-------------------|---------------|---------|-----------|
|             | Public sector     | Private sector |         |           |
|             | (n=526)           | (n=124)       | (n=401) | (n=95)    |
| Information is relevant for daily practice | 332 (63.1) | 61 (49.2) | 237 (59.1) | 52 (54.7) | 0.56 | 0.453 |
| Information is incorporated in clinical or professional society guidelines | 266 (50.6) | 45 (36.3) | 223 (55.6) | 52 (54.7) | 6.50 | **0.011** |

Statistically significant $p$-values are shown in bold. NPRA: National Pharmaceutical Regulatory Agency

**Respondents’ perspectives on enhancing medication risk communication**

In total, 195 respondents (17%) left 312 free-text comments, the majority of which (n=230; 73.7%) were suggestions for improvement. As shown in Fig. 3, five core themes on risk communication enhancement emerged from analysis of the comments and are supported by illustrative quotations from the participants.

**Awareness and publicity**

The most commonly recurring theme was to increase awareness of the risk communication methods especially among doctors and the private healthcare sector. “Never heard of NPRA, should consider promotion of this service” [respondent 179 (R179), doctor, 38 years]. “Reach out more to community pharmacy or general practitioner settings” (R021, pharmacist, 34 years). “I think the NPRA needs to be more present in platforms commonly accessed by doctors” (R120, doctor, 40 years). Respondents suggested increasing the presence of NPRA in social media. Many respondents were keen for virtual continuing medical education (CME) sessions on medication safety updates to be held regularly.

**Attractive and concise content**

Majority of respondents stated a preference for more concise, evidence-based, and original content. One respondent stated that the MADRAC Bulletin and Safety Alerts contained “mainly cut and paste” information (R030, doctor, 57 years). “Make the risk communication simple and succinct” (R022, pharmacist, 57 years). Many suggested the use of infographics, with a standardized layout to make all risk communication from the national regulatory authority easily recognizable.

**Dissemination**

Respondents preferred more frequent risk communication, with repetition of important messages. “NPRA needs to send same messages repeatedly so that we are aware” (R096, doctor, 52 years). Various suggestions were provided to improve the communication outreach, such as collaboration with
professional bodies, dissemination through trusted sources including pharmacists or the administrative heads of healthcare departments and sending brief safety alerts via mobile phone with links to further details.

**Technological advances**

Many respondents were keen for a mobile phone application to receive medication risk communication and suggested an “app with automatic messages on drug safety that can be tailored according to specialty area” (R029, doctor, 37 years). Some specific comments were also received regarding improvements required on the regulatory agency website. A number of respondents mentioned the creation of a repository of all previous medication risk communications as a reference source. “It would be great if NPRA could have an electronic repository, allowing healthcare professionals and patients to download safety information as required.” (R036, medical officer in the pharmaceutical industry, 36 years). “Recommend having a categorical listing of important updates and previous updates so that previous information which may have been missed over the years, remain relevant” (R058, pharmacist, 31 years).

**Implementation of risk minimization measures**

Several respondents left comments regarding the actual implementation of risk minimization measures or advice mentioned in the risk communication. “With electronic hospital information systems, good to incorporate automated safety alerts to warn prescribers at point of care” (R028, doctor, 39 years). “Ensure the risk communication is incorporated with changes in practice via circular to both doctors and pharmacists” (R080, pharmacist, 34 years). “Communication between Ministry of Health superiors and the implementing level must be clear and accurate” (R137, doctor, 46 years).

**Discussion**

This study aimed to assess the awareness of risk communication among doctors and pharmacists, identify factors which predict the usefulness of risk communication, and determine the methods they preferred for risk communication. The findings reveal that awareness of most risk communication methods is low. Six significant variables were identified that predict those who would find risk communication useful. These are ethnicity, job designation, employment setting, rural or urban areas, length of work experience, and training experience. Analysis of the survey responses revealed five core themes on enhancing risk communication.

Of the four available risk communication methods assessed, doctors and pharmacists had the highest awareness of educational materials. This is probably because these materials are often made available through multiple sources for a prolonged period,[22] resulting in increased awareness. About half of the respondents were aware of the MADRAC Bulletin and NPRA Safety Alerts which are directly distributed by the national regulatory authority, most of those aware being pharmacists from the public healthcare sector. Awareness was lowest for DHPCs, which are solely distributed by pharmaceutical companies to
users of the medicinal product mentioned in the letter. Our findings indicate that the methods of risk communication dissemination impact the awareness levels.

Almost 60% of respondents had never heard of DHPCs, although these communications have been widely used worldwide since 2012.[14] However, compared to healthcare professionals from the public sector, those from the private sector had a higher level of awareness of DHPCs. This is possibly because those from the private sector are more often directly involved in purchasing medication from the pharmaceutical companies. Internationally, studies have shown DHPCs to be ineffective due to several factors. DHPCs have been viewed as a defensive practice to transfer responsibility from manufacturers to prescribers, or a form of advertising as it is signed and distributed by the pharmaceutical companies.[14]

Surprisingly, our study found that DHPCs were the most effective risk communication method in prompting respondents to take the recommended risk minimization actions. An earlier study also showed DHPCs to be more effective than drug bulletins.[30] Thus, changes to the DHPC dissemination methods are needed to fully utilize this promising communication channel. Besides distribution by the pharmaceutical companies, the DHPCs could be made accessible online through regulatory authority websites to ensure coverage of both public and private sectors. A recent change made in Denmark could be adapted by other countries, whereby DHPCs are still signed by the industry but are disseminated by the Danish Medicines Agency to increase levels of trust.[14]

The national regulatory authority, Ministry of Health, and professional bodies emerged as the preferred sources of risk communication in this study, ahead of international regulatory agencies. This concurs with a previous study which reported that Asian health officials preferred guidance from in-country sources.[31] Trust in the source is a major factor in the success of risk communication, with low trust resulting in decreased uptake.[32] When organizations are not transparent in communicating risks, their credibility is reduced.[33] Our study shows that pharmacists are significantly more aware of medication risk communication compared to doctors, most likely because the Malaysian regulatory authority is part of the Ministry of Health Pharmacy Services Programme. A previous study on awareness of medication error reporting also revealed higher awareness among pharmacists.[18] Pharmacists are a trusted source of medication safety information for other healthcare professionals, patients and the public.[12, 34] As pharmacists are ideally placed across the country in various healthcare sectors, they can play a key role in increasing risk communication outreach to urban and rural areas, other healthcare professionals, policymakers, the pharmaceutical industry, and the general community. Regulatory authorities should conduct regular training for pharmacists on risk communication methods, latest safety issues and effective dissemination. Eventually, these trained pharmacists could serve as the trainers in their respective facilities.

Respondents’ preferences on risk communication as reported in this study are in agreement with the seven key aspects of effective communication, namely a trusted sender, relevant context and content, clear and concise wording, repetition of the message, use of multiple channels to reach target recipients, and suitable for capability of the audience [35, 36]. Therefore strategies to enhance risk communication should be planned based on these preferences.
Suggestions

Some key suggestions to enhance risk communication are as follows: (1) use multiple sources for dissemination; (2) produce concise and attractive content involving multiple stakeholders; (3) repeat important or urgent messages; (4) increase awareness of regulatory risk communication; (5) enhance existing channels of dissemination; (6) plan technological advances; and (7) improve training for both healthcare professionals and communicators.

Overall, our findings point towards public-private sector collaboration as the key to enhancing risk communication. The same message should be disseminated simultaneously by the national regulatory authority, pharmaceutical companies, and professional bodies to improve outreach as well as overcome trust issues. Further cascading of information by healthcare professionals in administrative departments and pharmacists from all sectors would increase effectiveness of risk communication.[37] Collaboration on technological developments such as mobile phone applications or websites for medication safety updates could also result in more effective systems than those created in silos. Ideally, important safety changes from the risk communication should be integrated into clinical practice guidelines and point-of-care alerts to increase uptake.[14]

Medication risk communication in Malaysia has evolved over the past 20 years.[13] Initially producing printed material solely targeting healthcare professionals, NPRA now utilizes electronic communication as well as social media, and disseminates information to consumers.[13] The quality of risk communication content may be enhanced through multidisciplinary collaboration, by inviting non-regulatory healthcare professionals and in the future, consumer group representatives or patients to contribute articles and commentaries. Involvement of different stakeholders with various perspectives would result in communication which appeals to a broader audience.[10]

Numerous respondents expressed a preference for risk communication in the format of concise infographics and using simple language. This finding is backed by a recent study emphasizing the use of plain language to get the message across in a transparent, actionable manner.[38] The amended risk communication format should be guided by design science, gathering input from users to make adjustments until the design is finalized.[10] This process would ensure the development of more effective communication tools.

One hurdle faced by regulatory authorities in risk communication is striking a balance between caution and timeliness.[6] Several respondents commented that the NPRA risk communication was delayed compared to the European Medicines Agency or the United States Food and Drug Administration. This is a problem faced by smaller regulatory authorities worldwide.[6] There is a need to develop a risk communication review and approval process which is precise yet prompt.[39] Regulatory authorities do need to practice caution to a certain extent, as the risk communications may elicit variable responses. This has been shown in numerous previous cases, where regulators have been accused of delayed action, secrecy, inaccurate benefit-risk assessment, and external commercial influence.[40, 41]
It is encouraging to note that respondents who have received training in medication safety had a significantly higher awareness of NPRA risk communication. However, this survey revealed that only half the doctors and 73% of pharmacists surveyed had received such training. This should be made an essential area of focus. Traditionally, NPRA conducts training on pharmacovigilance and medication safety via physical lectures and workshops.[42] However, the outreach of these methods is poor, and timing may be inconvenient for busy clinicians. The COVID-19 pandemic has accelerated the development of online tools for training, increasing familiarity and acceptance of virtual platforms to improve communication.[43] A recent study showed that a virtual boot camp had a significant impact on improving the knowledge and awareness of healthcare professionals.[44] As a number of our respondents suggested, regular virtual training programs should be conducted with flexible timing to accommodate the schedule of doctors. Effective training would increase awareness of risk communication as well as provide clinicians with the latest knowledge to ensure optimum patient safety.

The importance of training for risk communicators has also been highlighted in previous studies, that showed personnel trained in communications are key to risk communication success and should be given leadership roles.[45] These study findings highlight the need for intensive training on risk assessment and communication to take pharmacovigilance to the next level.

Besides the suggestions mentioned above, evaluation should be conducted for every risk communication effort implemented.[46] Audience feedback should be analyzed to determine further measures for improvement, as effective risk communication is a two-way process.[46, 47]

Undeniably, several stumbling blocks exist in the path towards enhancing risk communication in many countries,[6, 8] such as budget constraints for the development of communication technology systems and lack of highly trained personnel. Considering these issues, immediate suggestions from these findings emphasize the use of existing platforms to save cost, increase awareness, and reduce information overload for healthcare professionals, while long-term plans should involve technological advances.

**Limitations**

This study has several limitations. First, the use of non-probability sampling is not ideal but was unavoidable, as a list of complete sampling frame could not be obtained because of data protection issues. However, this limitation was minimized by obtaining a large sample size and responses from all states in Malaysia, including both urban and rural areas. The responses from doctors were lower than pharmacists, though their number is three times larger than pharmacists. While this was expected based on doctor response rates in other studies, it may increase the chances that data from doctors who responded are not representative of the population. Second, the use of an online survey platform may have excluded non-technologically savvy groups, such as those in areas without internet connection. Third, the entire survey was conducted while the COVID-19 pandemic was raging in Malaysia, therefore there may be a bias in terms of the groups who were likely to participate as many clinicians would have been very occupied with the pandemic response. Finally, our study is subject to the known biases of
cross-sectional, self-reporting survey methodology including recall bias, answering tendencies, and misunderstanding on terminology. However we reduced this limitation by validating the questionnaire with experts and piloting it among the target population. We also added qualitative research methods to provide a deeper understanding of the respondents’ preferences on risk communication. This will help guide the development of a strategic plan for enhancing medication risk communication.

**Future research**

Effective risk communication is a multi-stage process. The initial steps are for the message to be sent and received, as have been evaluated in this study. This paper could be used to reach out and collaborate with other stakeholders. The constructive comments and suggestions provided by the respondents have been categorized into different target areas. These could serve as a guide for focus group discussions involving all stakeholders to develop a specific, evidence-based, achievable and sustainable national strategic plan for the enhancement of risk communication.

Moving forward, we need to ensure the message is understood and prompts action or change in behaviour. Evaluation of risk communication effectiveness should be incorporated into the governance structure of regulatory agencies to ensure accountability.[6] National regulatory authorities could collaborate with the pharmaceutical industry and academia to conduct further studies evaluating the impact of risk communication on prescribing practice, ADR reporting rates, and health outcomes.

Following efforts to enhance communication between the regulatory authority and healthcare professionals, robust research must be conducted on communication with patients. A survey on doctor-patient communication should be carried out to determine the views and preferences of both parties. This would reveal if patients of a particular country are prepared to move towards the “partnership” model which is used in Western countries and has been adapted in many Asian countries.[48–50]

**Conclusions**

Awareness of medication risk communication needs to be increased, especially among doctors and private sector healthcare professionals. Given that effective risk communication is vital for medication safety, our findings have the potential to guide regulatory authorities towards developing national strategic plans for enhancing risk communication. Public-private sector collaboration must be enhanced to increase risk communication outreach and technological developments. Pharmacists are ideally placed and trusted, thus should play a key role as risk communicators in individual facilities.

**Abbreviations**

ADR: adverse drug reaction; CVI: content validity index; DHPC: Direct Healthcare Professional Communication; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; MOH: Ministry of Health; NPRA: National Pharmaceutical Regulatory Agency; WHO: World Health Organization
Declarations

Ethics approval and consent to participate

This study is registered under the National Institute of Health [NMRR-20-2215-56730 (IIR)] and received ethical approval from the Medical Review and Ethics Committee, Ministry of Health Malaysia (Ref: KKM/NIHSEC/ P20-2263). All methods were carried out in accordance with relevant guidelines and regulations. We performed the study is in accordance with the principles of the Declaration of Helsinki. Participation in this research was entirely voluntary. We provided all respondents with information on the study aims, procedures, risks, benefits, and protection for individual privacy. Written informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable

Availability of data and materials

The analysis results generated in the current study are presented in this published article. The research datasets will not be publicly available because they contain sensitive material, identifying participant information. The datasets generated for this study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This research did not receive funding from any agencies in the public, commercial, or not-for-profit sectors.

Authors' contributions

R.P. and Z.A. conceived and designed this study. R.P. developed the questionnaire, collected, analysed, and interpreted the data, and drafted the manuscript. Z.A. and A.K. reviewed the manuscript for important intellectual content. Z.A. supervised the data analysis and interpretation, critically revised the manuscript and provided final approval of the version to be submitted. All authors read and approved the final manuscript for publication.

Acknowledgements

We would like to thank the Director General of Health Malaysia, the NPRA pharmacovigilance team, and all participating healthcare facilities for supporting this study. We are very grateful to Sameerah Shaikh Abdul Rahman for providing expert advice on the questionnaire adaptation. Parts of this study and not
the entire content were presented as abstracts during the Association of Pacific Rim Universities Global Health Conference 2021 and the MAHSA International Pharmacy Conference 2021.

Authors' information

1 Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia. 2 National Pharmaceutical Regulatory Agency, Ministry of Health, 46200 Petaling Jaya, Malaysia. 3 Faculty of Pharmacy, MAHSA University, Bandar Saujana Putra, 42610 Jenjarom, Selangor, Malaysia.

References

1. World Health Organization (WHO). WHO Infodemic Management. 2020.
2. WHO. Risk communication Saves Lives & Livelihoods: Pandemic Inuenza Preparedness Framework. World Health Organization. 2015. https://www.who.int/publications/i/item/pip-risk-comms-saves-lives-livelihoods. Accessed 2 Jul 2021.
3. WHO. Medication Without Harm - Global Patient Safety Challenge on Medication Safety. Geneva; 2017.
4. Bahri P, Harrison-Woolrych M. Focusing on risk communication about medicines: Why now? Drug Safety. 2012;35:971–5.
5. Aitken M, Kleinrock M, Simorellis A, Nass D. The Global Use of Medicine in 2019 and Outlook to 2023. IQVIA Institute for Human Data Science. 2019; January:1–56.
6. Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, et al. Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology and Therapeutics. 2021;109:1424–42.
7. Chorus I, Bartram J. Toxic cyanobacteria in water. A guide to their public health consequences, monitoring, and management. E & FN Spon; 1999.
8. Bahri P, Dodoo AN, Edwards BD, Edwards IR, Fermont I, Hagemann U, et al. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance. Drug Safety. 2015;38:621–7.
9. WHO. World Health Organisation: Newsroom - Risk Communication. 2020. https://www.who.int/news-room/q-a-detail/risk-communication-frequently-asked-questions. Accessed 28 Aug 2020.
10. Bahri P. Communicating about risks and safe use of medicines: Real life and applied research. Singapore: Adis; 2020.
11. WHO. Joint external evaluation tool: International Health Regulations (2005). 2016.
12. Gaglio B, Glasgow RE, Bull SS. Do patient preferences for health information vary by health literacy or numeracy? a qualitative assessment. Journal of Health Communication. 2012;17 SUPPL. 3:109–21.
13. Panickar R, Wo WK, Ali NM, Tang MM, Ramanathan GRL, Kamarulzaman A, et al. Allopurinol-induced severe cutaneous adverse drug reactions: Risk minimization measures in Malaysia. Pharmacoepidemiology and Drug Safety. 2020;29:1254–62.

14. Møllebæk M, Kaae S. Why do general practitioners disregard direct to healthcare professional communication? A user-oriented evaluation to improve drug safety communication. Basic and Clinical Pharmacology and Toxicology. 2021;128:463–71.

15. Quek DKL. The Malaysian Health Care System: A Review. Intensive Workshop on Health Systems in Transition. 2014; July: https://www.researchgate.net/publication/237409933. Accessed 28 Aug 2021.

16. Chua GN, Yee LJ, Sim BA, Tan KH, Sin NK, Hassali MA, et al. Job satisfaction, organisation commitment and retention in the public workforce: A survey among pharmacists in Malaysia. International Journal of Pharmacy Practice. 2014;22:265–74.

17. DOSM. Statistics of medical services in Malaysia. 2020. https://www.dosm.gov.my/v1/index.php?r=column3/accordion&menu_id=amZNeW9vTXRydTFwTXAxSmdDL1J4dz09. Accessed 3 Sep 2021.

18. George D, HSS A-S, Hassali A. Medication Error Reporting: Underreporting and Acceptability of Smartphone Application for Reporting among Health Care Professionals in Perak, Malaysia. Cureus. 2018;10.

19. Samsiah A, Othman N, Jamshed S, Hassali MA. Knowledge, perceived barriers and facilitators of medication error reporting: a quantitative survey in Malaysian primary care clinics. International Journal of Clinical Pharmacy. 2020. https://doi.org/10.1007/s11096-020-01041-0.

20. de Vries ST, van der Sar MJM, Coleman AM, Escudero Y, Rodríguez Pascual A, Maciá Martínez MÁ, et al. Safety Communication Tools and Healthcare Professionals’ Awareness of Specific Drug Safety Issues in Europe: A Survey Study. Drug Safety. 2018;41:713–24.

21. NPRA. Malaysian Pharmacovigilance Guidelines 2nd Edition. 2016.

22. EMA. Guideline on good pharmacovigilance practices (GVP) - Module XVI – Risk minimisation measures: selection of tools and effectiveness indicators (Rev 3). 2021.

23. Yusoff MSB. ABC of Content Validation and Content Validity Index Calculation. Education in Medicine Journal. 2019;11:49–54.

24. Hadie SNH, Hassan A, Ismail ZIM, Asari MA, Khan AA, Kasim F, et al. Anatomy education environment measurement inventory: A valid tool to measure the anatomy learning environment. Anatomical Sciences Education. 2017;10:423–32.

25. Polit DF, Beck CT. The content validity index: Are you sure you know what’s being reported? Critique and recommendations. Research in Nursing & Health. 2006;29:489–97.

26. Polit DF, Beck CT, Owen S V. Focus on Research Methods: Is the CVI an Acceptable Indicator of Content Validity? Appraisal and recommendations. Research in Nursing & Health. 2007;30:459–67.

27. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code for Biology and Medicine. 2008;3.
28. Braun V, Clarke V, Hayfield N, Terry G. Thematic Analysis BT - Handbook of Research Methods in Health Social Sciences. Handbook of Research Methods in Health Social Sciences. 2019;:843–60.

29. Panickar R, Aziz Z, Kamarulzaman A. AB031. Medication risk communication: a cross-sectional survey among healthcare professionals in Malaysia. Journal of Public Health and Emergency. 2021;5:AB031–AB031.

30. Weatherburn CJ, Guthrie B, Dreischulte T, Morales DR. Impact of medicines regulatory risk communications in the UK on prescribing and clinical outcomes: Systematic review, time series analysis and meta-analysis. British Journal of Clinical Pharmacology. 2020. https://doi.org/10.1111/bcp.14104.

31. Parkhurst JO, Hyde A, South A, Brehmer L, Miller A, Newell JN. Improving communication of research findings: Identifying the sources of information most important to national disease control officers in low-and middle-income countries. Tropical Medicine and International Health. 2010;15:1252–5.

32. Löfstedt RE. Risk management in post-trust societies. Risk Management in Post-Trust Societies. 2005;1–165.

33. Hartigan-Go K. Challenges of drug risk communications in the Philippines. Drug Safety. 2012;35:995–1004.

34. Assanee J, Sorofman BA, Sirisinsuk Y, Kitisopee T. Factors influencing patient intention to report adverse drug reaction to community pharmacists: A structural equation modeling approach. Research in Social and Administrative Pharmacy. 2021. https://doi.org/10.1016/j.sapharm.2021.05.010.

35. Cutlip SM, Centre AH, Broom GM. Effective Public Relations. 6th edition. Englewood Cliffs, N.J.: Prentice-Hall; 1985.

36. Lang S, Fewtrell L, Bartram J. Risk communication: guidelines, standards and health. In: Water Quality: Guidelines, Standards and Health. London, UK: IWA Publishing; 2001. p. 16.

37. Hitchings AW, Wood DM, Dargan PI. Dissemination and uptake of a new treatment pathway for paracetamol poisoning in the UK: A survey of healthcare professionals. British Journal of Clinical Pharmacology. 2013;76:946–50.

38. Smith MY, Bahri P, Gaudino JA, Moreira RS, Danyluk GM, Palevsky SL. The role of epidemiologists in communicating SARS-CoV-2 evidence: a call for adopting standards. International Journal of Epidemiology. 2021;50.

39. Maor M. Organizational Reputations and the Observability of Public Warnings in 10 Pharmaceutical Markets. Governance. 2011;24.

40. de Vries ST, van der Sar MJM, Cupelli A, Baldelli I, Coleman AM, Montero D, et al. Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences. Drug Safety. 2017;40:729–42.

41. Møllebæk M, Kaae S, De Bruin ML, Callréus T, Jossan S, Hallgreen CE. The effectiveness of direct to healthcare professional communication – A systematic review of communication factor studies. Research in Social and Administrative Pharmacy. 2019.
42. NPRA. Annual Report 2020. 2020.
43. Adedoyin OB, Soykan E. Covid-19 pandemic and online learning: the challenges and opportunities. Interactive Learning Environments. 2020.
44. Abdullah B, Ramli RR, Shukri NM, Mohamad S. Closing the knowledge gap in Malaysian pharmacists: A virtual allergic rhinitis boot camp initiative. Multidisciplinary Respiratory Medicine. 2021;16.
45. Paulik LB, Keenan RE, Durda JL. The Case for Effective Risk Communication: Lessons from a Global Pandemic. Integrated Environmental Assessment and Management. 2020;16:552–4.
46. Ng KL, Hamby DM. Fundamentals for establishing a risk communication program. Health Physics. 1997;73:473–82.
47. Kain NA, Jardine CG. "Keep it short and sweet": Improving risk communication to family physicians during public health crises. Canadian Family Physician. 2020;66:e99–106.
48. Claramita M, Nugraheni MDF, van Dalen J, van der Vleuten C. Doctor-patient communication in Southeast Asia: A different culture? Advances in Health Sciences Education. 2013;18.
49. Moore M. What does patient-centred communication mean in Nepal? Medical Education. 2008;42.
50. Mudiyanse; Weerasinghe; Piyasinghe J. Patient’s Expectations during Doctor Patient Communication and Doctors Perception about Patient’s Expectations in a Tertiary Care Unit in Sri Lanka Abstract. iMedPub Journals. 2015;7.

Figures
Figure 1

Comparison between doctors and pharmacists on four risk communication methods used in Malaysia. 
(a) Awareness – “have seen and read it”, (b) Perceived usefulness, (c) How often they take the recommended risk minimization action. Chi-square test, **p < 0.001
DHPCs: Direct Healthcare Professional Communication letters; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; NPRA: National Pharmaceutical Regulatory Agency

Figure 2

Awareness of public and private sector respondents on four risk communication methods.

*p-values indicate differences between sectors. Chi-square test, *p < 0.05; **p < 0.001. DHPCs: Direct Healthcare Professional Communication letters; MADRAC: Malaysian Adverse Drug Reactions Advisory Committee; NPRA: National Pharmaceutical Regulatory Agency
Figure 3

Thematic map of healthcare professionals’ perspectives on medication risk communication

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1Contentvalidityindex.docx